positive Phase 1 clinical data for its novel kinesin spindle protein (KSP) inhibitor, ARRY-520. The data, which were presented at the 2010 Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, indicate that ARRY-520 was well tolerated and has shown encouraging preliminary results in the treatment of multiple myeloma. ARRY-520 is a novel, first-in-class, highly potent, selective KSP inhibitor currently being investigated in a single-agent Phase 2 clinical trial and a Phase 1b combination trial with bortezomib plus dexamethasone in patients with relapsed and refractory multiple myeloma. The poster is available as a PDF on Array's
See this Amp at http://bit.ly/hbToLF
No comments:
Post a Comment